GRO Biosciences has ended the week with an extra $60.3 million in the bank, which the protein therapeutics-focused biotech will use to push its lead gout treatment into clinical trials. nnGout occurs when high levels of uric acid in the blood cause crystals to form and accumulate in and around a joint, leading to pain and swelling. Horizon Therapeutics’ Krystexxa remains the only approved biologic to treat uncontrolled gout. But some patients who receive this uricase enzyme therapy soon develop anti-drug antibodies (ADAs) that clear out the enzyme, according to GRO.
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies
GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of distinguished gene therapy expert, Nicole Paulk, PhD, to its Scientific Advisory Board (SAB).
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will present at the 2022 BIO CEO & Investor Conference.